Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2008 by Asan Medical Center.
Recruitment status was:  Recruiting
Samsung Medical Center
Seoul National University Hospital
Kyunghee University Medical Center
Information provided by:
Asan Medical Center Identifier:
First received: July 18, 2008
Last updated: July 28, 2008
Last verified: July 2008


To describe the safety and efficacy of intravitreal flucinolone acetonide implants in the management of patients having refractory ocular Behcet's disease


A descriptive observational study

Study design:

A 1-year, multi-center (including four Korean medical centers) observational study

Condition Intervention Phase
Ocular Behcet's Disease,
Non-Infectious Uveitis
Refractory Uveitis
Drug: flucinolone acetonide
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease

Resource links provided by NLM:

Further study details as provided by Asan Medical Center:

Primary Outcome Measures:
  • Recurrence in the 36 wks, with one or more of the following events ->2 step Increase in the number of cells in the A/C -2 step increase in the vitreous haze -deterioration in visual acuity [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Post-implantation recurrence of uveitis rate: within-patient comparison of responding eyes (implant vs. fellow)and etc. [ Time Frame: 1 year ]

Estimated Enrollment: 15
Study Start Date: July 2008
Estimated Study Completion Date: May 2010
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
single group

Posterior uveitis patients having complete or incomplete type of Behcet's disease; typical ocular lesion and at least, one of the main symptoms or two of the additional symptoms.

Selection of study eye : For patients with unilateral uveitis, the study eye will be the affected eye; for patients with bilateral uveitis, the study eye will be the more severely affected eye (i.e., the eye having suffered more recurrences in the previous year, or if equal, the eye having received more therapy in the previous year, or if equal, the eye having the worse VA, or if equal, the eye clinically judged to be the more severely affected eye).

Drug: flucinolone acetonide
Intra-vitreal implantation of RETISERT on the study eye. The implant is a sustained-release delivery system containing 0.59 mg of flucinolone acetonide designed to deliver the drug for approximately 3 years.
Other Name: RETISERT

Detailed Description:
A multi-center, prospective single arm study to assess the efficacy and safety of retisert (intravitreal flucinolone acetonide 0.59 mg) in patients with refractory ocular Behcet's disease. This study will be conducted at 4 sites, located in Korea. The number of subject is expected approximately 15 patients. The medical records for the patients meeting following inclusion/exclusion criteria will be collected until 1 year after implantation.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and non-pregnant females at least 18 years of age having complete or incomplete type of Behcet's disease according to the revised diagnostic criteria proposed by the Behcet's Disease Research Committee of Japan in 2003; typical ocular lesion and at least, one of the main symptoms or two of the additional symptoms.
  • One or both eyes having a history of recurrent or chronic ocular Behcet's disease affecting the eye more than 1 year duration requiring either systemic corticosteroid or other equivalent systemic therapy for at least three months prior to enrollment; OR at least 2 sub-Tenon's injections of corticosteroid for the management of uveitis during the six months prior to enrollment; OR at least 2 separate recurrences within the six months prior to enrollment requiring either systemic corticosteroid therapy or sub-Tenon's injection of corticosteroids
  • At the time of enrollment the implanted eye must have: ≤ 10 anterior chamber cells/HPF and a vitreous haze ≤ grade 2
  • Visual acuity of at least 1.4 logMAR units (Snellen 20/500).

Exclusion Criteria:

  • Allergy to FA or any component of the delivery system
  • History of only posterior segment uveitis not accompanied by vitritis or macular edema
  • History of iritis only and no vitreous cells or vitreous haze
  • Uveitis with infectious etiology
  • Vitreous hemorrhage
  • Presence of a toxoplasmosis scar in the study eye
  • Peripheral retinal detachment in area of implantation
  • Media opacity precluding evaluation of the retina and vitreous
  • Uncontrolled increased intraocular pressure(IOP)(>21mmHg)at the time of retisert implantation
  • Ocular surgery on the study eye within 3 months prior to enrollment
  • Patients requiring chronic systemic corticosteroid therapy (>15mg prednisone daily) or systemic immunosuppressive therapy to manage non-ocular disease
  • Patients who have tested positive for human immunodeficiency virus
  • Pregnant or lactating females
  • Females of childbearing potential considering becoming pregnant during the course of the study and those not taking effective contraception/precautions to avoid pregnancy
  • Patients for whom, in the physician's opinion, any of the protocol procedures may pose a special risk not outweighed by the potential benefits of participating in the study
  • Patients who are unlikely to comply with the study protocol or who are likely to be moving and lost to follow-up in the 1 year
  • Patients who are currently enrolled in any other IND or investigational study or who have participated in an IND or investigational study within 1 month of enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00720928

Contact: Young Hee Yoon, MD 822-3010-3675
Contact: Don-Il Ham, MD 822-3410-3567

Korea, Republic of
Asan Medical Center Recruiting
Seoul, Korea, Republic of, 138-736
Contact: Young Hee Yoon, MD    822-3010-3680   
Contact: Don-Il Ham, MD    822-3410-3567   
Sponsors and Collaborators
Asan Medical Center
Samsung Medical Center
Seoul National University Hospital
Kyunghee University Medical Center
Principal Investigator: Young Hee Yoon, MD Asan Medical Center
  More Information

Responsible Party: Young Hee Yoon, MD/Professor and Chairman, Asan Medical Center Identifier: NCT00720928     History of Changes
Other Study ID Numbers: RTS-2008-1
Study First Received: July 18, 2008
Last Updated: July 28, 2008

Keywords provided by Asan Medical Center:
Behcet's disease
posterior uveitis
flucinolone acetonide

Additional relevant MeSH terms:
Behcet Syndrome
Uveal Diseases
Eye Diseases
Mouth Diseases
Stomatognathic Diseases
Vascular Diseases
Cardiovascular Diseases
Hereditary Autoinflammatory Diseases
Genetic Diseases, Inborn
Skin Diseases, Genetic
Skin Diseases
Skin Diseases, Vascular
Uveitis, Anterior
Fluocinolone Acetonide
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on May 25, 2017